Nutraceutix, a US producer of ingredients and technologies for the nutraceutical industry, is to sell its D-glucarate business to another licensor of the product, BioChemix. Under the terms of the agreement Nutraceutix gained $480,570 (525.442 euros) from the sale and will discontinue all sales, marketing, and distribution activities related to D-Glucarate. In the fiscal year 2000, Nutraceutix had gross revenues of $774,000 (846,271 euros) from the sale of bulk D-glucarate raw material. BioChemix will continue marketing D-glucarate through its joint venture partner, Glucona BV. David Howard, President & CEO of Nutraceutix, Inc. commented," This agreement allows Nutraceutix to focus on our core business strategy going forward, which has changed considerably with the acquisition of new intellectual property in both our probiotic business and our novel and patented CDT™ technologies. We are now able to concentrate on business opportunities aligned with our core competencies and intellectual property position."